Topotecan
"Topotecan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
Descriptor ID |
D019772
|
MeSH Number(s) |
D03.132.151.850
|
Concept/Terms |
Topotecan- Topotecan
- 9-Dimethylaminomethyl-10-hydroxycamptothecin
- 9 Dimethylaminomethyl 10 hydroxycamptothecin
- Hycamtamine
Topotecan Hydrochloride- Topotecan Hydrochloride
- Hydrochloride, Topotecan
- Topotecan Monohydrochloride, (S)-Isomer
- Nogitecan Hydrochloride
- Hydrochloride, Nogitecan
SK&F-104864-A- SK&F-104864-A
- SK&F 104864 A
- SK&F104864A
- SKF-104864-A
- SKF 104864 A
- SKF104864A
Hycamtin- Hycamtin
- SmithKline Beecham Brand of Topotecan Hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Topotecan".
Below are MeSH descriptors whose meaning is more specific than "Topotecan".
This graph shows the total number of publications written about "Topotecan" by people in this website by year, and whether "Topotecan" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 3 | 3 | 1995 | 0 | 1 | 1 | 1996 | 1 | 2 | 3 | 1997 | 0 | 1 | 1 | 1998 | 2 | 1 | 3 | 2000 | 1 | 0 | 1 | 2001 | 1 | 2 | 3 | 2002 | 1 | 2 | 3 | 2004 | 1 | 0 | 1 | 2005 | 1 | 1 | 2 | 2006 | 2 | 1 | 3 | 2007 | 0 | 2 | 2 | 2008 | 0 | 1 | 1 | 2009 | 1 | 0 | 1 | 2010 | 0 | 2 | 2 | 2011 | 1 | 0 | 1 | 2013 | 1 | 0 | 1 | 2019 | 0 | 1 | 1 | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Topotecan" by people in Profiles.
-
Nelson AT, Bendel A, Skrypek M, Patel S, Tabori U, McDonald W, Schultz KAP. Leptomeningeal Dissemination of Low-Grade Neuroepithelial Tumor with FGFR1_TACC1 Fusion with Clinical and Radiographic Response to Pazopanib and Topotecan. Pediatr Neurosurg. 2022; 57(1):63-68.
-
Oza AM, Matulonis UA, Alvarez Secord A, Nemunaitis J, Roman LD, Blagden SP, Banerjee S, McGuire WP, Ghamande S, Birrer MJ, Fleming GF, Markham MJ, Hirte HW, Provencher DM, Basu B, Kristeleit R, Armstrong DK, Schwartz B, Braly P, Hall GD, Nephew KP, Jueliger S, Oganesian A, Naim S, Hao Y, Keer H, Azab M, Matei D. A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clin Cancer Res. 2020 03 01; 26(5):1009-1016.
-
Salgia S, Fleming GF, Lukas RV. Leptomeningeal carcinomatosis from breast cancer treated with intrathecal topotecan with concomitant intravenous eribulin. J Clin Neurosci. 2014 Jul; 21(7):1250-1.
-
Park JR, Scott JR, Stewart CF, London WB, Naranjo A, Santana VM, Shaw PJ, Cohn SL, Matthay KK. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011 Nov 20; 29(33):4351-7.
-
Lopez KA, Tannenbaum AM, Assanah MC, Linskey K, Yun J, Kangarlu A, Gil OD, Canoll P, Bruce JN. Convection-enhanced delivery of topotecan into a PDGF-driven model of glioblastoma prolongs survival and ablates both tumor-initiating cells and recruited glial progenitors. Cancer Res. 2011 Jun 01; 71(11):3963-71.
-
Garassino MC, Torri V, Michetti G, Lo Dico M, La Verde N, Aglione S, Mancuso A, Gallerani E, Galetta D, Martelli O, CollovĂ E, Fatigoni S, Ghidini A, Saggia C, Bareggi C, Rossi A, Farina G, Thatcher N, Blackhall F, Lorigan P, Califano R. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung Cancer. 2011 Jun; 72(3):378-83.
-
Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol. 2010 Jun; 117(3):473-6.
-
Grinblatt DL, Yu D, Hars V, Vardiman JW, Powell BL, Nattam S, Silverman LR, de Castro C, Stone RM, Bloomfield CD, Larson RA. Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). Cancer. 2009 Jan 01; 115(1):84-93.
-
Ji YB, Zhou JH, Zuo MX, You QD. [Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo]. Yao Xue Xue Bao. 2008 Aug; 43(8):811-8.
-
Miller AA, Wang XF, Bogart JA, Hodgson LD, Rocha Lima CM, Radford JE, Vokes EE, Green MR. Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. J Thorac Oncol. 2007 Jul; 2(7):645-51.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|